Regencell Bioscience Holdings (RGC) Accumulated Expenses (2020 - 2025)

Regencell Bioscience Holdings (RGC) has 6 years of Accumulated Expenses data on file, last reported at $1.4 million in Q4 2025.

• Quarterly Accumulated Expenses changed N/A year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (changed N/A YoY) and the FY2025 annual result came in at $348354.0, up 177.95% from the prior year.
• Accumulated Expenses climbed to $1.4 million in Q4 2025, from $348354.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.4 million in Q4 2025 to a low of $125328.0 in Q2 2024.
• A 5-year average of $460579.2 and a median of $253217.5 in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses jumped 503.15% — and 2022, when it tumbled 73.62%.
• Tracing RGC's Accumulated Expenses over 5 years: stood at $572990.0 in 2021, then plunged by 73.62% to $151127.0 in 2022, then gained by 4.6% to $158081.0 in 2023, then slipped by 20.72% to $125328.0 in 2024, then jumped by 1023.13% to $1.4 million in 2025.
• The last three Accumulated Expenses figures came in at $1.4 million (Q4 2025), $348354.0 (Q2 2025), and $125328.0 (Q2 2024), per Business Quant data.